The review of works on erythropoietin (rEpo) usage in cardio-vascular diseases is represented in the article. It is shown that there are several research groups working in this field in the world. Cardioprotective properties of erythropoietin after its introduction in case of myocardial ischemia are revealed. It blocks apoptosis of endothelium, influences the reduction of the hypertrophied left ventricle, diminishes remodeling of left ventricle at patients with myocardial infarction and chronic cardiac insufficiency. Presence of endothelial and cardiac protective properties of rEpo can be pre-condition of the clinical use of this medication in patients with different kinds of ischemic heart disease. Introduction of rEpo requires research of its hypertensive and oncologic safety at a course or, even, single application before use in clinical practice.
